Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 36.2% in October

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 95,100 shares, a growth of 36.2% from the October 15th total of 69,800 shares. Based on an average daily trading volume, of 1,340,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.2% of the shares of the company are short sold.

Vivos Therapeutics Stock Performance

NASDAQ VVOS opened at $2.84 on Friday. Vivos Therapeutics has a fifty-two week low of $1.91 and a fifty-two week high of $48.79. The firm has a market capitalization of $13.53 million, a P/E ratio of -0.40 and a beta of 7.71. The stock has a 50-day simple moving average of $2.79 and a two-hundred day simple moving average of $2.52.

Vivos Therapeutics (NASDAQ:VVOS) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. The company had revenue of $4.05 million during the quarter. Vivos Therapeutics had a negative net margin of 85.90% and a negative return on equity of 652.32%. As a group, analysts forecast that Vivos Therapeutics will post -3.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets increased their price objective on shares of Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research note on Tuesday, August 20th.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.